Snapshot from Jul 30, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Insilico-CMS second CNS collaboration
Business drug discovery partnership

Insilico-CMS second CNS collaboration

Analysis based on 6 articles · First reported Jul 13, 2026 · Last updated Jul 13, 2026

Sentiment
40
Attention
3
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The collaboration reinforces Insilico Medicine's position as a leading AI-driven drug discovery platform, potentially boosting investor confidence and stock valuation. For CMS, the partnership enhances its pipeline with innovative CNS therapies, which could strengthen its market position in China.

biotechnology pharmaceuticals
Event Summary

Insilico Medicine and Inspire Medical Systems (CMS) announced a second AI-powered drug discovery collaboration in three months, targeting a mass-market central nervous system (CNS) indication using a novel mechanism of action identified by Insilico's PandaOmics platform. Under the agreement, Insilico is eligible to receive up to approximately 1.2 billion RMB in milestone payments plus royalties. The partnership combines Insilico's generative AI drug discovery capabilities with CMS's clinical development, regulatory, and commercialization expertise. This deal follows Insilico's earlier collaborations with Eli Lilly, Qilu Pharmaceutical, SK Biopharmaceuticals, and Bicara Therapeutics, signaling a shift to an active out-licensing and co-development model.

Key Actions
80 Insilico Medicine announced collaboration Inspire Medical Systems
60 Insilico Medicine identified novel MoA
50 Insilico Medicine entered collaboration Eli Lilly and Company
50 Insilico Medicine entered collaboration SK Biopharmaceuticals
40 Insilico Medicine entered collaboration Qilu Pharmaceutical
30 Insilico Medicine advanced co-development Bicara Therapeutics
Entities Involved
priv
Insilico Medicine
Insilico deepens its partnership with CMS, securing up to 1.2 billion RMB in milestones and royalties, reinforcing its AI platform's productivity and out-licensing strategy.
Importance 100.0 Sentiment 60.0
stock
Inspire Medical Systems
CMS expands its CNS pipeline through a second collaboration with Insilico, leveraging its clinical and commercial infrastructure to advance AI-discovered drug candidates.
Importance 90.0 Sentiment 50.0
per
Khlong Lam Kong
As CMS Chairman and CEO, Khlong Lam Kong publicly endorsed the partnership, highlighting strategic complementarity.
Importance 30.0 Sentiment 0.0
per
Feng Ren
As Insilico Co-CEO and CSO, Feng Ren expressed enthusiasm for the deepened collaboration and the innovative MoA identified by PandaOmics.
Importance 30.0 Sentiment 0.0
stock
Eli Lilly and Company
Eli Lilly is mentioned as a prior collaborator with Insilico, but is not directly involved in this event.
Importance 10.0 Sentiment 0.0
priv
Qilu Pharmaceutical
Qilu Pharmaceutical is mentioned as a prior collaborator with Insilico, but is not directly involved in this event.
Importance 10.0 Sentiment 0.0
stock
SK Biopharmaceuticals
SK Biopharmaceuticals is mentioned as a prior collaborator with Insilico, but is not directly involved in this event.
Importance 10.0 Sentiment 0.0
priv
Bicara Therapeutics
Bicara Therapeutics is mentioned as a co-development partner for Insilico's CNS program, but is not directly involved in this event.
Importance 10.0 Sentiment 0.0
exch
Ghana Stock Exchange
Both Insilico and CMS are listed on the Ghana Stock Exchange, but the exchange is not directly impacted by this event.
Importance 5.0 Sentiment 0.0
exch
Singapore Exchange
CMS is also listed on the Singapore Exchange, but the exchange is not directly impacted by this event.
Importance 5.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.